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Abstract
For genome-wide association studies in family-based designs, we propose a powerful two-stage testing strategy that can be
applied in situations in which parent-offspring trio data are available and all offspring are affected with the trait or disease
under study. In the first step of the testing strategy, we construct estimators of genetic effect size in the completely
ascertained sample of affected offspring and their parents that are statistically independent of the family-based association/
transmission disequilibrium tests (FBATs/TDTs) that are calculated in the second step of the testing strategy. For each
marker, the genetic effect is estimated (without requiring an estimate of the SNP allele frequency) and the conditional
power of the corresponding FBAT/TDT is computed. Based on the power estimates, a weighted Bonferroni procedure
assigns an individually adjusted significance level to each SNP. In the second stage, the SNPs are tested with the FBAT/TDT
statistic at the individually adjusted significance levels. Using simulation studies for scenarios with up to 1,000,000 SNPs,
varying allele frequencies and genetic effect sizes, the power of the strategy is compared with standard methodology (e.g.,
FBATs/TDTs with Bonferroni correction). In all considered situations, the proposed testing strategy demonstrates substantial
power increases over the standard approach, even when the true genetic model is unknown and must be selected based on
the conditional power estimates. The practical relevance of our methodology is illustrated by an application to a genome-
wide association study for childhood asthma, in which we detect two markers meeting genome-wide significance that
would not have been detected using standard methodology.
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Introduction
Recent advances in mapping array technology and the
increasing content from SNP databases [1,2] have expanded the
capacity for large-scale genotyping. With mapping arrays for more
than one million SNPs now available [3,4,5,6], genome-wide
association studies carry the promise of identifying replicable
associations between important genetic risk factors and complex
diseases. One of the major hurdles that needs to be addressed in
order to make genome-wide association studies successful is the
multiple comparison problem. Hundreds of thousands of SNPs are
genotyped and examined for potential associations with multiple
phenotypes, resulting in possibly millions of statistical tests. The
small number of SNPs that contain ‘‘true’’ signals must be
identified among the thousands of false-positive results. The
success of genome-wide association studies will depend upon
whether it will be possible to overcome this obstacle and translate
the increase in genotype information into the identification of
novel disease loci, or whether the increased genetic information
will be diluted by the multiple testing problem.
A brute-force way to address the multiple comparison problem is
to designstudies with sample sizes large enough to test all genotyped
SNPs with standard association tests and adjust for multiple
comparison using the Bonferroni correction [7]. However, while
sample sizes of severalthousand subjects will certainly be feasible for
common phenotypes (e.g., BMI, height), such a strategy carries the
riskthat the increase insamplesizeisaccompaniedbyanincrease in
study heterogeneity, mitigating the positive effects of a larger sample
size. Further, for many diseases, recruiting the theoreticallyrequired
sample size may not be feasible, prohibited either by the costs for
recruitment or phenotype assessment, or by the prevalence of the
disease. An alternative approach is to develop novel statistical
methodology to address the multiple comparison problem with
realistic sample sizes.
For the analysis of quantitative traits in family-based designs,
Van Steen et al. [8] proposed a new class of two-stage testing
strategies that uses the same data set twice, first for genomic
screening and then for genetic association testing. The approach
proved to be a very powerful way to address the multiple testing
problem in genetic association studies [8,9,10,11]. Van Steen type
testing strategies take advantage of a unique property of family-
based data in that it can be partitioned into two statistically
independent components. By exploiting the information about the
genetic association that is not used in the second stage when the
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ising’’ SNPs for the second stage.
Van Steen type testing strategies have three key advantages: 1.)
The method achieves statistical power levels which can be
substantially higher than those of standard approaches [8,9], and
is thereby able to establish genome-wide significance within one
study [8,9,10,11]. 2.) The Van Steen algorithm maintains the
separation between the multiple testing problem and the
replication process. Replication attempts in different studies are
reserved for the generalization of the established associations and
assessment of heterogeneity between study populations. 3.) Since
genome-wide significance is established in the first data set, the
number of SNPs that are pushed forward for replication testing in
other populations is generally very small and does not require a
large budget, which makes simultaneous replication attempts in
multiple samples feasible.
Although the approach has recently been significantly improved
and now allows family studies to achieve power levels that are
comparable to population-based studies with the same number of
probands [9], its applicability is limited. While extensions of the
testing strategy are available for arbitrary family structures and for
case/control designs [10,11], the approach cannot be applied in
situations in which there is no phenotypic variation in the
phenotypes of the probands, i.e., all probands are affected with the
disease or trait of interest. This prevents the utilization of the
approach in trio designs (i.e., affected probands and their parents).
Since this original trio/TDT design is frequently used, this
limitation of the testing strategy poses a major disadvantage for
family-based designs.
In this manuscript, we propose an extension of Van Steen type
testing strategies to family-based designs in which all probands are
affected. The strategy also uses the same data set for both stages,
which we will refer to as the rank-weighting step and the testing
step. In the first stage of the testing strategy, the genetic relative
risk effect sizes are estimated for each SNP. We show that it is
possible to derive four estimating equations that depend only on
the observed parental mating types, but not on any unknown
parameters. The estimating equations can be solved analytically,
allowing for the construction of effect size estimators that do not
depend on the marker allele frequency or offspring genotypes.
This is in contrast to effect size estimators/association test statistics
for study designs with only affected subjects in population-based
studies [12,13,14], where the allele frequency must be specified.
Based on the genetic effect size estimates obtained from the
estimating equations, we compute the conditional power of the
FBAT/TDT for all SNPs. The relative rank of the SNPs by
conditional power is then used in a weighted Bonferroni approach
[9] to assign each SNP an individually adjusted significance level.
The weights are constructed so that the overall type-1 error is
maintained. In the second step of the testing strategy, the FBAT/
TDT statistic is computed for each SNP and genome-wide
significance is established based on its individually adjusted
significance level.
Using extensive simulation studies, the statistical power of the
testing strategy is assessed for over a range of genetic effect sizes,
different numbers of trios, when the mode of inheritance is known
and unknown, and in the absence and presence of linkage
disequilibrium (LD). The practical relevance of the approach is
illustrated by an application to a genome-wide association study of
childhood asthma.
Methods
An Overview of Partitioning Family-Based Data into
Independent Components
Van Steen testing strategies for genome-wide association studies
partition the data set into two statistically independent, but
overlapping parts [8,9,10,11,15,16]. In family-based designs, the
first component contains information about the SNP-trait
association at a population level, which is assessed based on the
proband’s phenotype, Y, and the parental genotypes, P1, P2
[15,17]. In our application, we use the offspring phenotype and
parental genotypes to construct effect size estimates of the genetic
relative risk. The second component of the data characterizes the
SNP-trait association at the family level, i.e., the allele transmis-
sions from the parents to their offspring [18,19,20]. Family-based
association tests such as the TDT or FBAT are therefore
conditional tests that treat the offspring genotype, X, as random,
conditioning upon the offspring phenotype, Y, and the parental
genotypes P1, P2. The evidence for SNP-trait association is
evaluated by comparing the observed offspring genotype with the
expected offspring genotype, which are computed by conditioning
upon the parental genotypes, assuming Mendelian transmissions.
Since the offspring genotype is the only random component of the
FBAT/TDT statistic, the implication is that other information in
the FBAT/TDT statistic (i.e., the offspring phenotype and
parental genotypes) may be used to assess the evidence for
association without biasing the significance level of the FBAT/
TDT statistic.
Based on the two information sources about association in
family-based designs, the density of the joint distribution for X, Y,
and P1, P2 can then be partitioned into two statistically
independent components [21],
pX ,Y,P1,P2 ðÞ ~pXY ,P1,P2 j ðÞ |pY ,P1,P2 ðÞ : ð1Þ
Since the density for the first step of the testing strategy, the rank-
weighting step, is given by p(Y, P1, P2), and the density of the
second step, the FBAT/TDT testing step, is p(X|P1, P2, Y),
likelihood decomposition (Equation 1) implies that the two steps of
Author Summary
The current state of genotyping technology has enabled
researchers to conduct genome-wide association studies
of up to 1,000,000 SNPs, allowing for systematic scanning
of the genome for variants that might influence the
development and progression of complex diseases. One of
the largest obstacles to the successful detection of such
variants is the multiple comparisons/testing problem in
the genetic association analysis. For family-based designs
in which all offspring are affected with the disease/trait
under study, we developed a methodology that addresses
this problem by partitioning the family-based data into
two statistically independent components. The first
component is used to screen the data and determine
the most promising SNPs. The second component is used
to test the SNPs for association, where information from
the screening is used to weight the SNPs during testing.
This methodology is more powerful than standard
procedures for multiple comparisons adjustment (i.e.,
Bonferroni correction). Additionally, as only one data set
is required for screening and testing, our testing strategy is
less susceptible to study heterogeneity. Finally, as many
family-based studies collect data only from affected
offspring, this method addresses a major limitation of
previous methodologies for multiple comparisons in
family-based designs, which require variation in the
disease/trait among offspring.
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(i.e., the genetic effect size estimate) for each marker from the
rank-weighting step can be utilized in the second stage without
having to adjust the overall significance level for the estimation of
the genetic effect size in the first stage. There are various ways in
which the information from the rank-weighting step can inform
the application of the FBAT/TDT statistic in the second step. The
effect size estimate from the screening step can be used to select a
small subset of ‘‘very promising’’ markers for FBAT/TDT testing
[8] or to assign each marker with an individual significance level
that reflects the rank of the marker’s effect size estimate relative to
the other markers [9]. Another possibility is to have the
information from the screening step define the ‘‘tuning parame-
ters’’ of the FBAT statistic [22,23].
The Rank-Weighting Step: Estimating the Power of the
FBAT Statistic under HA When Trio Data Are Given and All
Probands Are Affected
We assume that trios are given (i.e., affected probands and
parents), and that SNP data are analyzed. If the parental data are
missing/unavailable, the parental genotypes can be replaced in all
equations below by the sufficient statistic by Rabinowitz & Laird
[18,19]. The sufficient statistic for each nuclear family is defined
by all family configurations that lead to consistent inference about
the missing parents, given the observed genotypes. When parental
data are given, the parental genotypes represent the sufficient
statistic. Like the parental genotypes, the sufficient statistic allows
for the computation of the offspring genotype distribution within
each family, independent of the unknown allele frequency. For a
more detailed discussion, we refer to the original paper [18].
For each marker locus of interest, let xi be the coded genotype of
the i
th proband, counting the number of minor alleles for the SNP
of interest. The variables pi1 and pi2 denote the parental genotypes
for both parents at the locus. The phenotype of the i
th proband is
defined by yi. For trio samples in which all probands are affected,
the phenotype is coded as ‘‘y=1’’. The FBAT statistic, x2
FBAT,
[19,20] is then given by:
x2
FBAT~
X n
i~1
xi{Ex i pi1,pi2 j ðÞ ½ 
() 2 ,
X n
i~1
Var xi pi1,pi2 j ðÞ * x2
1 ð2Þ
and has a chi-square distribution with one degree of freedom.
Assuming an additive coding function for the genotype, this FBAT
statistic and the original TDT statistic [20] are equivalent.
In order to develop a Van Steen type testing strategy [15,16] for
the classical TDT design, the conditional power [22,24] of the
FBAT/TDT statistic, x2
FBAT, has to be computed in the first step
of the testing strategy. This requires the specification of the
conditional marker density under the alternative hypothesis:
PHA xi pi1,pi2,yi~1 j ðÞ
~
fxi Pr xi pi1,pi2 j ðÞ
P 2
e x x~0
fe x x Pr e x xp i1,pi2 j ðÞ
~
Yxi Pr xi pi1,pi2 j ðÞ
P 2
e x x~0
Ye x x Pr e x xp i1,pi2 j ðÞ
, ð3Þ
where affected probands are coded as ‘‘yi=1’’. The parameter fx
denotes the penetrance probability (i.e., fx=Pr(yi=1|x)), and Yx,
the genotype relative risk (i.e., Yx=fx/f0). The probability Pr(x|pi1,
pi2) is defined by Mendelian transmission and can be computed
straightforwardly, conditional on parental genotypes, without any
additional knowledge/assumptions. The penetrance probabilities
fxi~Pr yi~1 xi j ðÞ are unknown and have to be estimated based on
the information that is available in the rank-weighting step, i.e.,
the offspring phenotype and the parental genotypes.
In the original Van Steen approach [8], the parental genotypes
are used to compute the expected/predicted marker scores of the
offspring. By regressing the offspring phenotype on its expected
marker score, an estimate for the genetic effect size is obtained that
allows us to specify the penetrance probability, Pr(yi=1|xi) [15,16].
However, when there is no phenotypic variation in the data (i.e.,
all probands are affected), this approach is not applicable and an
alternative approach has to be developed. In order to simplify the
notation, our derivation will be based on the parameterization of
the marker distribution (Equation 3) in terms of the genotype
relative risks, Yx.
Due to the lack of variation in the phenotype, the only variation
that can be utilized for the estimation of the relative risk
probabilities are the parental genotypes. In the trio design, there
are six distinct parental mating types: (p1=2, p2=2), (p1=2,
p2=1), (p1=2, p2=0), (p1=1, p2=1), (p1=1, p2=0) and (p1=0,
p2=0), where 0, 1, and 2 denote the number of copies of the minor
allele for the marker of interest. The frequencies of the parental
mating types in the ascertained sample (yi=1) can be computed
using Bayes’ rule,
pkl : ~Pr p1~k,p2~ly ~1 j ðÞ
~
P 2
e x x~0
Ye x x|Pr e x xp 1~k,p2~l ðÞ j ðÞ |Pr p1~k,p2~l ðÞ
1{p ðÞ
2z2p 1{p ðÞ Y1zp2Y2
; ð4Þ
where the parameter, p, denotes the minor allele frequency for the
marker in the general population, and again, as above, the
probabilities Pr e x xp 1~k, p2~l ðÞ j ðÞ are defined by Mendelian
transmissions. The probabilities Pr(p1=k, p1=l) are the paternal
mating type frequencies in the general population, and k and l are
given by one of the six distinct mating types defined above. Under
the assumption of random mating and Hardy-Weinberg equilib-
rium at the marker locus in the general population, the
probabilities Pr(p1=k, p1=l) will be defined by the actual mating
type and the minor allele frequency, p.
Based on these assumptions, the likelihood of the parental
mating types in the ascertained sample is given by
l Y1,Y2,p ðÞ ~pn22
22 pn21
21 pn20
20 pn11
11 pn10
10 pn00
00 , where the probability of a
mating type is denoted as pp1p2 and the observed number of
mating types is np1p2. In order to obtain maximum likelihood
estimates for the genotype relative risks Y1 and Y2, one has to
maximize the likelihood function l(Y1, Y2, p) over all unknown
parameters, i.e., the genotype relative risks, Y1 and Y2, and the
minor allele frequency of the marker, p. However, due to the
structure of the likelihood function, the Fisher information matrix
is ill conditioned [25] and a numerical solution of the likelihood
maximization is non-trivial. This is particularly challenging in the
context of genome-wide association studies in which the numerical
implementation must be fast and reliable. In addition to the
technical issues related to the likelihood maximization, the
estimation of the allele frequency at the marker locus is also
problematic in the presence of population admixture.
To avoid issues related to the estimation of the allele frequency,
we will construct estimators for the genotype relative risks, Y1 and
Y2, that are independent of the minor allele frequency, p, and
have a closed analytical form, facilitating a numerically fast and
robust implementation in genome-wide association studies. We
consider the following four possible ratios of parental mating types:
Testing Strategies for Trios
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p22   p00
p2
20
R2 : ~
p10   p11
p00   p21
R3 : ~
p00   p21
p20   p10
R4 : ~
p21   p10
p20   p11:
ð5Þ
Under the assumption of Hardy-Weinberg equilibrium in the
general population, using (Equation 4), the minor allele frequency,
p, drops out of the mating type ratios, and one can show that the
ratios R1, R2, R3, and R4 are given by:
R1~ Y2
4Y2
1
R2~
1zY1 ðÞ 1z2Y1zY2 ðÞ
Y1zY2
R3~ Y1zY2
2Y1 1zY1 ðÞ R4~
2 Y1zY2 ðÞ 1zY1 ðÞ
Y1 1z2Y1zY2 ðÞ :
8
<
:
ð6Þ
It is important to note that the four ratios R1, R2, R3, and R4 do
not depend on the unknown minor allele frequency, p, and can be
estimated based on the parental genotypes, e.g., ^ R R1~n221n00
 
n2
20.
It is also important to note that, if a likelihood approach for the
parental mating types had been implemented, the minor allele
frequency, p, would have to be estimated.
If a genetic model is specified (e.g., under an additive mode of
inheritance, Y1=(1+Y2)/2), each equation in (Equation 6) will
depend only on one unknown genotype relative risk parameter.
Each equation can then be solved for the unknown parameter and
four estimates for the genotype relative risk are obtained.
Alternatively, an overall effect size estimate can be constructed
by averaging over all four estimates for the genetic effect size. The
selected estimate for the genotype relative risk can then be used to
calculate the marker distribution under the alternative hypothesis
(Equation 3), which is the final component needed in calculating
the conditional power of the FBAT/TDT statistic. Using
simulation studies, we will assess which of the four ratios (or the
average) for the proposed testing strategy generally achieves the
highest and most stable power estimates.
Since the proposed estimators for the genotype relative risk only
depend on the parental genotypes, they fulfill the decomposition
condition (Equation 1) and can be used in the rank-weighting step
of the testing strategy without biasing the significance level of the
FBAT/TDT statistic in the second stage. The independence of the
mating type ratios from the allele frequency makes the approach
particularly attractive in the presence of population admixture.
While we have outlined the concept of genotype relative risk
estimation in the context of ascertained family samples for the trio
designs, the genetic effect size estimators can be constructed in the
same way for more complex nuclear family structures. Using the
algorithm by Rabinowitz & Laird [18], all possible parental
mating types can be derived for nuclear families with missing
parental information and/or multiple offspring. The mating type
probabilities can then be computed based on Bayes’ rule, as for the
trio design (Equation 4). By examining all possible mating type
ratios, the ratios that depend only on the genotype relative risk, but
not on the allele frequency, can be identified and used to construct
direct estimators of the genetic effect size. While we are not able to
provide a general rule of thumb on how to construct mating type
ratios that do not depend on the allele frequency other than to
evaluate all possible ratios, such ratios appear to exist for most
nuclear family-types. Since the identification process of the
suitable mating type ratios can be automated by using software
packages such as Maple and Mathematica, the proposed concept
of genotype relative risk estimation is not specific to the trio design
and should be applicable to general nuclear family-types.
It is important to note that the proposed genetic effect size
estimators are derived under the assumption of Hardy-Weinberg
equilibrium at the marker locus in the general population, but not
in the ascertained sample. Since it is common practice to filter out
SNPs that are strongly out of Hardy-Weinberg equilibrium when
the genotype data are cleaned prior to analysis, only SNPs with
mild to moderate violations of the Hardy-Weinberg assumption
will reach the association analysis step. The effects of SNPs with
Hardy-Weinberg violations on the proposed testing strategy are
thereby limited. However, the genetic effect size estimation in the
first step will be biased for such SNPs. In the presence of SNPs that
are out of Hardy-Weinberg equilibrium and that are not
associated with affection status, the proposed testing strategy is
likely to have reduced power. If the Hardy-Weinberg assumption
does not hold at the disease susceptibility locus (DSL), the power of
the proposed testing strategy can be either increased or decreased,
depending on whether the signal that is caused by the true genetic
effect at the DSL locus is amplified by the Hardy-Weinberg
violation or not. Further, it is important to note that, while
violations of the Hardy-Weinberg assumption will have an effect
on the rank-weighting step, the validity of the FBAT/TDT-testing
step and, consequently, the validity of the entire approach will not
be affected by departures from Hardy-Weinberg.
The Testing Step: Testing for Family-Based Association
with Weighted Bonferroni Significance Levels
In the first phase of the testing strategy, the genetic effect size
estimates for each marker are used to compute the conditional
power at each locus, and all markers are ranked by power. A
weighted Bonferroni approach [9] is implemented that assigns
individual significance levels, denoted as ai, to each marker locus
based on its conditional power ranking. Essentially, ai is the type 1
error apportioned to the i
th test on the basis of its power ranking
relative to all of the other tests. The individual significance levels
are selected so that the overall significance level is maintained, e.g., P
ai~0:05. Using the FBAT/TDT statistic, each marker is then
tested in the second stage at the individual significance level ai, and
its association with affection status is declared as genome-wide
significant if its FBAT/TDT statistic p-value is less than the
individual significance level ai.
In order to determine the individual significance levels ai,w e
must select a weighting scheme to apply to the weighted
Bonferroni method [9]. Essentially, the weighted Bonferroni
method partitions the SNPs into bins and assigns each bin a
weight, where the bin and weight sizes vary depending on the
relative power ranking of the SNPs in the bin. Each SNP within a
bin is assigned an equal weight, which represents a fraction (or
individual significance level, ai) of the overall significance level, a.
Many different weighting schemes to select bin/weight sizes may
be applied, as long as a is maintained. We selected an exponential
weighting scheme, which uses weights that decrease exponentially
and bin sizes that increase exponentially as the power rankings
decrease [9]. To define the exponential weighting scheme, let kj be
the size of the j
th partition, and let k and r be user-defined
partitioning parameters with an integer value. Then the sizes of
the subsequent partitions can be defined by k1=k and kj=k*r
(j21).
The exponential weight, wj, for the j
th bin is given by
wj~ r{1
r | 1
r j{1 ðÞ , with
P
j wj~1. Finally, the individual signifi-
cance level for the j
th partition/bin is
wj
ki |a. With these parameter
specifications, it is straightforward to see that
P
ai~a, thus the
overall alpha level is maintained. Further discussion of the
weighted Bonferroni method and weighting schemes is given in
Ionita-Laza et al. [9]. The optimal choices for the initial partition
Testing Strategies for Trios
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simulation studies.
Simulation Studies
Using simulation studies, we compare the proposed testing
strategy to the standard approach, FBAT/TDT testing with
Bonferroni corrected p-values. Both approaches are contrasted
under various scenarios with differing trio sample sizes and minor
allele frequencies. We simulate trio data under the assumption that
all offspring are affected and the genotypes of both parents are
known. The minor allele frequencies are drawn from b
distributions that resemble the 550 K Illumina HumanHap array.
The data were simulated under two separate scenarios. In the
first scenario, independence among all markers (i.e., no linkage
disequilibrium (LD)) is assumed. In the second scenario, we
simulated local LD between the SNPs. In order to obtain realistic
local LD patterns, we utilized a 550 K scan in the CAMP study
(see Data Analysis section) that consists of 400 trios. Based on the
observed local LD patterns in CAMP, we simulated the correlated
SNPs for the second scenario. Specifically, we applied a ‘moving
window’ algorithm, where the observed correlation (r
2) between
the SNP to be simulated and the SNP immediately preceding the
SNP that is simulated (in terms of physical location) was used to
recapitulate local LD patterns on a genome-wide scale.
In each simulation, one locus/SNP is assumed to be the DSL,
while the other SNPs that are not in LD with the DSL are
considered null loci. For the null loci, under the independence
scenario, the parental genotypes are generated by drawing from a
Binomial distribution with the selected marker’s minor allele
frequency. When SNPs are correlated, the moving window
approach described above is used to generate parental genotypes.
Based on the parental genotypes, the offspring genotype is
obtained by simulated Mendelian transmissions from the parents.
At the DSL, the configuration of genotypes in the proband and
parents is simulated based on their theoretical distribution under
the specified alternative hypothesis, as outlined in Knapp [26] and
Lange & Laird [22,24].
For the considered scenarios, we assessed the performance of
the proposed approach when the genetic effect size is estimated
either based on one of four mating type ratios (R1–R4, Equation
6) or by the average of the four estimates. In simulation studies
comparing the performance of the estimators (data not shown), we
observed that the genotype relative risk estimator based on
equation R4 consistently generated the highest power estimates
(for minor allele frequencies (MAFs) .0.1), and was stable, even
with modest effect sizes (e.g., OR=1.25) and lower allele
frequencies (e.g., MAF#0.2). Thus, all estimated power levels
for the proposed method that are shown here are based on the
genotype relative risk estimator for mating type ratio R4.
In the first set of simulations, we assume an additive mode of
inheritance at the DSL. The genetic effect size is defined in terms
of an odds ratio and ranges between 1.25 and 2.5, depending on
the number of trios. A disease prevalence (K) of 10% is selected
throughout the simulations. The trio sample size varies between
500–2000 trios. To accurately depict the degree of LD between
markers, 500,000 markers are simulated. Under the independence
scenario, the power was assessed as the proportion of replicates
where the FBAT test statistic p-value was less than the required
weighted Bonferroni alpha level, based on its power ranking from
the rank-weighting step. Under the LD scenario, the power was
computed in two ways. First, we defined a positive result
identically to the procedure used for the independence scenario
(i.e., a significant result for the DSL only). Secondly, we more
broadly defined a positive result to include a significant finding in
the DSL or in any markers in strong LD (r
2.0.8) and within the
same physical region, (i.e., within five SNPs) with the DSL. For the
standard Bonferroni correction, power was defined as the
proportion of replicates with an FBAT statistic p-value,10
27
(i.e., 0.05/500,000).
Estimated Power Levels for n=500–2000 Trios, under an
Additive Genetic Model
The results of the first set of simulations are displayed in Table 1.
The number of trios is presented in column 1 and the odds ratio
(OR) for the DSL is specified in column 2. The minor allele
frequency (MAF) of the DSL is displayed in Column 3. Columns
4, 6, and 8, denoted as ‘‘Weighted,’’ present the power estimates
using the weighted Bonferroni method by Ionita-Laza et al. [9],
with an exponential weighting scheme and partitioning parame-
ters of K=7 and r=2. The choice of K=7 and r=2 tended to
have the highest power among a range of partitioning (K=3–10,
r=2–5) parameters, although decreases in power were minimal
within these ranges (data not shown). Columns 5, 7, and 9,
denoted as ‘‘Standard,’’ display the results for the standard
approach in which all SNPs are equally weighted when applying
the Bonferroni correction, and a significance level of 10
27, (i.e.,
0.05/500,000) is required for genome-wide significance. Columns
4–5 (Independence scenario’’) reflect the scenario in which all
markers are independent (i.e., adjacent r
2=0). Columns 6–9 (‘‘LD
scenario’’) display the power estimates when LD is present among
markers, where the power represents either detecting the DSL
only (Column 6–7), or the DSL/markers in strong LD with the
DSL (Columns 8–9). The power estimates are based on at least
1,000 replicates for each (DSL) minor allele frequency and odds
ratio.
For genome screens of 500 K SNPs, regardless of the sample
size or degree of correlation among markers, the use of power-
driven weights from the rank-weighting step shows a considerable
improvement in power over the standard methodology. For the
lowest power estimates (,40% power for the standard Bonfer-
roni), the power estimates for the weighted method are typically at
least twofold greater than the standard approach. For low to
moderate power estimates, (40–70% power for Bonferroni), the
weighted method outperforms the standard correction by to 15–
40%. For SNPs with greater than 70% power with the standard
approach, the improvement ranges between 7 and 11%, unless the
power estimates are near one. However, even in these scenarios,
the power estimates for the weighted Bonferroni method are
always higher, though the differences between the two methods
are more modest.
With respect to trio sample size, we note that even with smaller
sample sizes (e.g., n=500), there is still power to detect a DSL (or
SNP in LD with the DSL), and the power gains over standard
Bonferroni correction are maintained, although a more pro-
nounced effect size is required (OR=2.25–2.5) to achieve
adequate power. Based on the results of our simulation studies,
we would not recommend genome-wide association studies of
fewer than 300 trios unless extremely large effect sizes (OR.3)
were anticipated.
To verify that the proposed testing strategy maintains the
overall alpha level, the simulations were repeated under the null
hypothesis of no linkage/no association, with a sample size of 500
trios. Based on over 10,000 replicates, the observed overall type 1
error rate was maintained at 4.66%.
Finally, in examining the impact that LD has on power, when
considering a positive finding to be the detection of the DSL
only, the power of the approach was slightly reduced in
comparison to the scenario in which the SNPs were indepen-
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the standard approach by differences that are of practical
relevance. When the definition of a positive finding is extended
to those SNPs that are in LD with the DSL, the power estimates
are higher than the independence scenario. This is a significant
finding, given that some array platforms for genome-wide
genotyping do not employ LD-tagging methods, and as chip
density increases (i.e., one million SNP arrays), linkage
disequilibrium will have a greater impact on the analysis of
genome-wide association studies.
Table 1. Power for 500–2000 trios and 500K markers, using mating type ratio equation R4, under an additive genetic model.
Number Odds MAF Independence scenario LD scenario (DSL only) LD scenario (DSL+)
of Trios Ratio Weighted Standard Weighted Standard Weighted Standard
2000
1.25 0.1 0.066 0.003 0.042 0.001 0.127 0.017
0.2 0.241 0.039 0.168 0.012 0.391 0.147
0.3 0.295 0.089 0.203 0.031 0.513 0.300
0.4 0.270 0.129 0.165 0.048 0.504 0.366
1.375 0.1 0.226 0.078 0.154 0.033 0.371 0.195
0.2 0.591 0.388 0.454 0.212 0.800 0.665
0.3 0.744 0.591 0.590 0.397 0.921 0.857
0.4 0.764 0.666 0.591 0.465 0.930 0.893
1.5 0.1 0.517 0.357 0.390 0.225 0.722 0.604
0.2 0.908 0.846 0.827 0.703 0.985 0.964
0.3 0.976 0.952 0.931 0.874 0.995 0.992
0.4 0.979 0.969 0.940 0.902 0.997 0.995
1000
1.5 0.1 0.100 0.032 0.072 0.018 0.170 0.084
0.2 0.354 0.189 0.271 0.113 0.520 0.352
0.3 0.470 0.336 0.360 0.220 0.667 0.555
0.4 0.456 0.371 0.333 0.248 0.660 0.571
1.75 0.1 0.438 0.324 0.345 0.236 0.581 0.488
0.2 0.859 0.777 0.770 0.658 0.940 0.901
0.3 0.932 0.896 0.881 0.819 0.976 0.960
0.4 0.936 0.904 0.881 0.839 0.976 0.964
2 0.1 0.825 0.759 0.750 0.669 0.918 0.876
0.2 0.992 0.985 0.984 0.970 0.999 0.997
0.3 0.998 0.996 0.994 0.990 1.000 1.000
0.4 0.997 0.995 0.994 0.989 0.998 0.997
500
2 0.1 0.184 0.128 0.132 0.085 0.276 0.205
0.2 0.573 0.480 0.490 0.382 0.693 0.606
0.3 0.711 0.628 0.635 0.538 0.805 0.740
0.4 0.665 0.590 0.591 0.505 0.771 0.707
2.25 0.1 0.447 0.350 0.367 0.278 0.551 0.473
0.2 0.849 0.787 0.797 0.720 0.916 0.878
0.3 0.905 0.868 0.869 0.811 0.954 0.928
0.4 0.894 0.856 0.849 0.805 0.934 0.900
2.5 0.1 0.694 0.612 0.624 0.542 0.793 0.729
0.2 0.957 0.934 0.935 0.895 0.981 0.967
0.3 0.978 0.964 0.966 0.943 0.991 0.982
0.4 0.965 0.949 0.945 0.919 0.983 0.975
Estimated power levels to detect the DSL using 500–2000 trios, assuming a 10% disease prevalence and additive mode of inheritance. The significance level is set to 5%.
For the weighted Bonferroni method (Weighted), the partitioning parameters are K=7 and r=2. MAF denotes minor allele frequency. The power reflects the proportion
of times the p-value of the DSL (Independence scenario and LD scenario (DSL only)) or a SNP in LD with the DSL (LD scenario (DSL+)) met the weighted Bonferroni
(Weighted) or standard Bonferroni corrected (Standard) significance level. The standard Bonferroni correction adjusts for 500 K comparisons.
doi:10.1371/journal.pgen.1000197.t001
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Genetic Model Is Unknown
Since in practice the underlying mode of inheritance is unknown,
we rana second setofsimulationsto reflect this realityand assessthe
impact on the power of the proposed method and the standard
approach. In the data analysis step of the following simulation, the
true genetic model was considered to be ‘‘unknown.’’ We simulated
three scenarios, wherethe true (but unknown) generatingmodel was
either additive, dominant, or recessive, and conducted separate
FBAT analyses under all three genetic models. To evaluate the
power for the weighted Bonferroni method [9], we estimated the
conditional power for each SNP under all three genetic models. For
each SNP, the result for the genetic model with highest power was
selected and the lower powered results (without evaluating the
FBAT statistic p-value) were discarded. This resulted in 500,000
SNPs/power estimates across the three genetic models, that were
ranked overall by power and evaluated for association using
weighted Bonferroni significance levels. The weighted Bonferroni
significance levels were computed in the same way as previously
described. We then compared the power obtained from the
weighted method to standard Bonferroni correction, which
computed the FBAT statistic under all three genetic models at
each SNP, thus requiring a correction for 1.5 million comparisons
(500,000 markers * 3 genetic models) and an FBAT p-value
,3.3610
28 for significance (i.e., 0.05/1,500,000). For simplicity,
we ran these simulations for 2000 trios.
The results of the second set of simulations are displayed in
Table 2. The data are presented in an identical format to the
simulations under the additive model (including partitioning
parameters of K=7 and r=2), except that column 1 reflects the
‘‘true’’ underlying genetic model rather than the number of trios.
For the additive model, in comparison to the simulations where
the genetic model is known, the power estimates tend be slightly
lower. In the independence scenario, for an odds ratio of 1.5 and
MAF of 0.2, when the genetic model is known, the weighted
Bonferroni method has 91% power versus 85% for the standard,
whereas, when the genetic model is unknown, the power estimates
are 80% and 57%, respectively. However, our new method seems
much more robust to analysis under multiple models in
comparison to the standard correction. For an effect size of 1.5,
the power loss in the unknown model ranges from 7 to 15%,
depending on MAF, while power loss under the standard method
ranges from 15 to 63%. Similar observations are made for the
power comparisons between the weighted and standard methods
for the LD scenarios. The overall power is reduced relative to the
situation where the generating genetic model is known, but the
difference in power between the weighted and standard methods is
more striking. In comparing the independence scenario to the LD
scenarios, the patterns observed when the genetic model is known
hold here as well: when LD is present and the DSL or SNPs in LD
with the DSL are considered, the power is highest, followed by the
independence scenario. The lowest overall power is noted when
LD is present and only the DSL is examined for significant
association. In summary, while the overall power drops, the
benefits of our methodology versus the standard are more
pronounced when the genetic model is unknown and multiple
analyses are conducted.
In comparing our method with weighted Bonferroni signifi-
cance levels to the standard under dominant and recessive models,
our procedure consistently demonstrates greater power, regardless
of the degree of LD, effect size, or MAF. However, under a
recessive model, a MAF of 0.3 or greater is required to achieve
adequate power for the range of effect sizes that we examined
(OR=2–2.5).
Overall, our new methodology has the greatest impact for the
low to moderately powered markers. For SNPs with standard
Bonferroni power estimates ranging between 40% and 70%, the
new method generally boosts power by an absolute difference of
10–15%, potentially providing marginally powered SNPs with a
better chance of detection.
Summary
Our simulation studies illustrate that the application of the
proposed testing strategy is not limited by the number of trios
analyzed, the degree of correlation among SNPs, the genetic model,
or the size of the genetic effect. When standard approaches fail to
provide sufficient power, the proposed testing strategy maintains
acceptable power levels for small to moderate effect sizes (n=2000)
for the additive generating models, and moderate effect sizes under
thedominant or recessivemodelsor designswithfewer trios(n=500–
1000). As a general rule of thumb, our simulation experiments suggest
that the testing strategy achieves optimal power levels for partitioning
parameters of K=7 and r=2 for 500,000 markers, though power
estimates were similar for K=5–10 and r=2–3. A comparison of the
achieved power levels for differing number of trios and various
genetic models illustrates that the impact of the multiple testing
problem on a genome-wide association study can be minimized by
the use of the proposed testing strategy.
Data Analysis: A Genome-Wide Screen of Children
Asthmatics
Asthma is a complex respiratory disorder, likely due to both
genetic and environmental influences that affect the developing
respiratory system. Asthma has been shown to have substantial
heritability [27,28,29] and a comprehensive review of the
literature in 2003 reported more than 200 studies with an
association between asthma and its related phenotypes [30].
Thus, we applied our methodology to a family-based genome-
wide association study of asthma. The families were originally
recruited through the Childhood Asthma Management Program
(CAMP) [31] Genetics Ancillary Study. All of the families were
ascertained through asthmatic probands between 5 and 12 years
old with mild to moderate asthma. All of the probands are
affected, making it impossible to apply methodologies that require
phenotype variation.
SNP genotyping was performed using Illumina HumanHap
550v3 arrays. Of 547,645 SNPs, 2.5% were removed during data
cleaning due to genotype completion rates ,95%, parent-offspring
Mendelian errors, or because the assay sequence could not be
aligned to one genomic locus, which resulted in 534,290 autosomal
markers for analysis.Genotyping was conducted on 1215 subjects in
422 families. After removing 43 subjects with inadequate data, 1172
subjectscomprising 403families wereanalyzed.Weappliedthenew
power rank-weighting methodology, under an additive genetic
model, to all 534,290 SNP, using equation R4 (Equation 6) to
estimate genetic effect sizes, which had consistently had the highest
power in the simulation studies. The power rankings were used to
individually weight the family-based association test (also assuming
an additive model) for each marker, using the method of Ionita-
Laza et al. [9]. Table 3 displays the results for the CAMP data
analysis. Based on the results of the simulation studies, the
partitioning parameters of K=7 and r=2 were used.
From the analysis, two SNPs were identified as genome-wide
significant with a global alpha level of 0.05. These SNP were also
the top two by power. Thus, the Top K Method by Van Steen et
al. [8], with a modest choice of ‘Top’ markers selected for analysis,
would have also detected these SNPs. However, the weighted
Bonferroni method by Ionita-Laza et al. [9] allows for the
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have been detected after standard Bonferroni [7] or FDR-type
[32] correction. These significant markers reside on chromosomes
1 (rs10863712) and 14 (rs1294497). In both markers, the minor
allele is over-transmitted to the affected proband. These markers
are currently under further study. These results provide proof of
concept for our new method in that the top-ranked markers by
power also showed evidence of association, strongly suggesting
Table 2. Power for 2000 trios and 500K markers, using mating type ratio equation R4, under an ‘‘unknown’’ genetic model.
True Gen. Odds MAF Independence scenario LD scenario (DSL only) LD scenario (DSL+)
Model Ratio Weighted Standard Weighted Standard Weighted Standard
Add.
1.25 0.1 0.033 0.001 0.019 0.000 0.074 0.005
0.2 0.140 0.008 0.085 0.002 0.265 0.055
0.3 0.175 0.022 0.109 0.007 0.320 0.122
0.4 0.137 0.029 0.083 0.007 0.305 0.174
1.375 0.1 0.140 0.026 0.098 0.008 0.256 0.092
0.2 0.414 0.171 0.316 0.085 0.623 0.430
0.3 0.537 0.332 0.373 0.166 0.777 0.644
0.4 0.532 0.404 0.376 0.241 0.793 0.711
1.5 0.1 0.354 0.183 0.281 0.107 0.546 0.385
0.2 0.790 0.646 0.669 0.466 0.928 0.876
0.3 0.910 0.844 0.802 0.694 0.984 0.967
0.4 0.916 0.878 0.817 0.742 0.985 0.973
Dom.
1.5 0.1 0.207 0.099 0.135 0.053 0.360 0.230
0.2 0.376 0.257 0.271 0.154 0.597 0.490
0.3 0.306 0.218 0.200 0.129 0.522 0.443
0.4 0.145 0.104 0.072 0.046 0.263 0.204
1.75 0.1 0.760 0.690 0.642 0.548 0.896 0.856
0.2 0.937 0.910 0.862 0.808 0.988 0.979
0.3 0.906 0.868 0.821 0.758 0.967 0.951
0.4 0.693 0.624 0.577 0.503 0.830 0.784
2 0.1 0.989 0.984 0.970 0.959 1.000 0.999
0.2 1.000 0.999 0.999 0.999 1.000 1.000
0.3 0.997 0.995 0.993 0.992 0.999 0.998
0.4 0.965 0.950 0.935 0.911 0.987 0.982
Rec.
2 0.1 0.002 0.000 0.002 0.000 0.002 0.000
0.2 0.011 0.005 0.008 0.003 0.019 0.007
0.3 0.217 0.165 0.147 0.104 0.335 0.267
0.4 0.767 0.723 0.657 0.598 0.887 0.867
2.25 0.1 0.003 0.000 0.002 0.000 0.006 0.000
0.2 0.039 0.014 0.029 0.010 0.057 0.029
0.3 0.562 0.463 0.450 0.373 0.704 0.620
0.4 0.971 0.959 0.949 0.927 0.991 0.985
2.5 0.1 0.005 0.000 0.004 0.000 0.007 0.000
0.2 0.103 0.053 0.068 0.036 0.155 0.087
0.3 0.850 0.784 0.783 0.709 0.926 0.884
0.4 0.997 0.995 0.995 0.991 1.000 1.000
Estimated power levels to detect the DSL using 2000 trios, assuming a 10% disease prevalence. The significance level is set to 5%. For the weighted Bonferroni method
(Weighted), the partitioning parameters are K=7 and r=2. ‘‘Under True Gen. Model’’, Add. refers to the scenario where the true (but ‘‘unknown’’) model is additive (as
the results are analyzed using all three genetic models). Similar scenarios are provided for the dominant (Dom.) and recessive (Rec.) genetic models. MAF denotes minor
allele frequency. The power reflects the proportion of times the p-value of the DSL (Independence scenario and LD scenario (DSL only)) or a SNP in LD with the DSL (LD
scenario (DSL+)) met the weighted Bonferroni (Weighted) or standard Bonferroni corrected (Standard) significance level. The standard Bonferroni correction adjusts for
1.5 M comparisons (500 K markers
* 3 genetic models).
doi:10.1371/journal.pgen.1000197.t002
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family level components of family-based data.
Discussion
With the current genotyping capabilities, genome-wide associ-
ation studies have become a reality. In order to utilize the wealth
of SNP data obtained in such studies to identify genes for complex
diseases, new statistical approaches are needed that can handle the
multiple comparisons problem on an increasingly large scale. For
population-based studies, multi-stage designs have been suggested.
In each stage of the design, the ‘‘most promising’’ SNPs (top 1–
10% of all genotyped SNPs) are pushed forward to the next level
in which they are genotyped in another sample. Overall
significance is established by combining the evidence from all
stages into a single analysis. While this is a cost-effective approach,
it is not as powerful as genotyping all subjects [33].
Testing strategies that use the samedata set for genomic screening
(i.e., rank-weighting) and testing [8,9,10,11] establish genome-wide
significance within one data set. They usually identify only a handful
of SNPs (typically fewer than 20) which are then genotyped in other
studies in order to generalize the significant findings [34,35]. In
contrast to multi-stage designs, genotyping the identified SNPs in
other samples does not serve the purpose of establishing genome-
wide significance. The effects of study heterogeneity are thereby
limited. However, thus far, such testing strategies have only been
available for the small subset of family-based studies in which the
primary phenotype is quantitative, but not for the most popular
family design, the classical trio design. The lack of phenotypic
variation has prevented the genetic effect size estimation by the
conditional mean model in the rank-weighting step.
In this manuscript, we have developed an approach that makes
suchtesting strategies available for the commonly used TDTdesign.
Our simulation studies show that our method outperforms standard
methodologysubstantially. The effectsize estimatorsthat wesuggest
allow for the assessment of the genotype relative risk at a population
level in ascertained family samples. In contrast to association tests
for affected-only designs in population-based studies [12,13,14],
here it is possible to estimate the genetic effect size independent of
the unknown allele frequency. While we have discussed only the
construction of such effect size estimators for the trio design, the
concept of identifying probability ratios of mating types that depend
onthe geneticeffect size,butnot ontheunknown allelefrequency,is
generally applicable to all family-based designs.
URL
The testing strategy as well as the corresponding power and
sample size calculations has been fully implemented in the
software package PBAT, which is freely available at http://www.
biostat.harvard.edu/,clange/default.htm [36,37].
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